BRCA1 and breast carcinoma: Recently, a PARP (poly-ADP-polymerase) inhibitor—through the underlying mechanism of inhibiting DNA repair, has demonstrated good efficacy against BRCA1-associated breast cancer, which usually refers to TNBCs.